AstraZeneca

Showing 15 posts of 769 posts found.

Cutting-edge cancer treatments showcased at ESMO

October 18, 2010
Research and Development AstraZeneca, Boehringer, Cancer, Cancer Conference, Johnson & Johnson, Novartis, personalised medicine

The search for a ‘silver bullet’ against cancer has failed, for now, with the battle against the disease turning instead …

AZ plans heart attack study for Brilique

October 8, 2010
Research and Development, Sales and Marketing AstraZeneca, Brilinta, Brilique

AstraZeneca is due to begin enrolling patients into a new study of its oral antiplatelet Brilique (ticagrelor) before the end …

AZ-BMS diabetes drug impresses in phase III trials

October 1, 2010
Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes

AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …

Late stage cancer drug failure for AstraZeneca

September 27, 2010
Sales and Marketing AstraZeneca, prostate cancer, zibotentan

AstraZeneca’s oncology pipeline has suffered a further blow after prostate cancer drug zibotentan failed to meet its primary endpoint of …

Solid results for AstraZeneca’s oral RA drug

September 23, 2010
Research and Development AstraZeneca, Rigel, fostamatinib, rheumatoid arthritis

AstraZeneca’s new oral treatment for rheumatoid arthritis has produced solid results in a phase II trial. Fostamatinib is the first …

AZ signs cancer development deal

September 13, 2010
Research and Development AstraZeneca, CRT, Cancer Research UK

AstraZeneca has agreed a deal with charity Cancer Research UK to develop a first-in-class cancer treatment. AZD-3965 targets the monocarboxylate …

AZ’s Seroquel extends European licence

September 3, 2010
Sales and Marketing AstraZeneca, Seroquel

AstraZeneca’s controversial anti-psychotic drug Seroquel has been given the green light in Europe as an add-on treatment for serious depressive …

AZ

AstraZeneca staff to strike over pension cuts

August 17, 2010
Sales and Marketing AstraZeneca, pensions

AstraZeneca is reviewing its position after UK trade union members at the company voted to strike over cuts to pension …

AstraZeneca reaches $200m Seroquel settlement

August 10, 2010
Sales and Marketing AstraZeneca, Seroquel

AstraZeneca is to pay around £198 million to settle US lawsuits against its troubled anti-psychotic drug Seroquel. The company has …

FDA recommends Brilinta

July 30, 2010
Sales and Marketing 2010 financials, AstraZeneca, Brillinta, Q2

FDA advisors have voted in favour of AstraZeneca’s antiplatelet drug Brilinta, which is currently seeking a licence for the reduction …

Dr Bruce Burlington joins AZ board

July 30, 2010
Research and Development, Sales and Marketing AstraZeneca, appointment, research and development, sales and marketing

AstraZeneca has appointed former FDA staffer Dr Bruce Burlington to its board as a non-executive director. Dr Burlington spent 17 …

AstraZeneca extends siRNA collaboration

July 14, 2010
Research and Development AstraZeneca, RNA, Silence Therapeutics

AstraZeneca has agreed a one-year extension on its siRNA development collaboration with London-based Silence Therapeutics. Silence is a specialist in …

AstraZeneca collaborates on compound library

July 5, 2010
Research and Development AstraZeneca, MRC

AstraZeneca and the UK’s Medical Research Council are to share access to their compounds to improve their efforts to find …

European Court upholds AZ Losec judgement

July 2, 2010
Sales and Marketing AstraZeneca, Losec, generics

The General Court of the EU has upheld the European Commission’s 2005 decision that AstraZeneca were guilty of blocking cheaper …

Crestor victory lifts AstraZeneca

July 1, 2010
Sales and Marketing AstraZeneca, Crestor

AstraZeneca has defeated a challenge to the US patent on its blockbuster cholesterol drug Crestor. A US District Judge in …

Latest content